Research and Development Expenses Breakdown: AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.

AstraZeneca vs. Catalyst: R&D Investment Strategies Unveiled

__timestampAstraZeneca PLCCatalyst Pharmaceuticals, Inc.
Wednesday, January 1, 2014557900000010117774
Thursday, January 1, 2015599700000011801342
Friday, January 1, 2016589000000011369941
Sunday, January 1, 2017575700000011375237
Monday, January 1, 2018593200000019919204
Tuesday, January 1, 2019595800000018842752
Wednesday, January 1, 2020599100000016496715
Friday, January 1, 2021973600000016936000
Saturday, January 1, 2022976200000019789000
Sunday, January 1, 20231093500000093150000
Monday, January 1, 202413583000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Innovators: AstraZeneca vs. Catalyst Pharmaceuticals

In the ever-evolving landscape of pharmaceutical research, AstraZeneca PLC and Catalyst Pharmaceuticals, Inc. stand as intriguing contrasts. Over the past decade, AstraZeneca has consistently invested heavily in research and development (R&D), with expenses peaking at approximately $10.9 billion in 2023, marking a 96% increase from 2014. This commitment underscores AstraZeneca's role as a global leader in pharmaceutical innovation.

Conversely, Catalyst Pharmaceuticals, a smaller player, has shown a more modest yet significant growth in R&D spending. From 2014 to 2023, their expenses surged by over 800%, reaching nearly $93 million. This growth reflects Catalyst's strategic focus on niche markets and specialized treatments.

The data highlights the diverse strategies of these companies: AstraZeneca's broad-spectrum approach versus Catalyst's targeted innovation. As the pharmaceutical industry continues to evolve, these differing strategies offer valuable insights into the future of drug development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025